General Info

Elixir Pharmaceuticals is a biopharmaceutical company that utilizes aging research to develop pharmaceuticals that treat and/or prevent metabolic diseases, such as obesity and diabetes. The company is able to pursue its mission through its assemblage of a comprehensive technology platform in the biology and molecular genetics of aging and disease that includes the largest commercially consented collection of centenarian genomes and medical histories; laboratory organism models of human aging and metabolic disease; the capability to predictably translate information from laboratory organisms to human genes, physiological pathways, diseases and drugs; and the capability to validate its drug development pipeline in diabetes and obesity, as well as other age-related diseases. Elixir Pharmaceuticals is supported by investors ARCH Venture Partners, MPM Capital, Oxford Bioscience Partners and Perennial Ventures. Elixir Pharmaceuticals is based in Cambridge, Mass.